Nasopharyngeal Cancer Market Report and Forecast 2024-2032

Nasopharyngeal Cancer Market Outlook

The nasopharyngeal cancer market size is expected to grow at a CAGR of 2.2% during the forecast period of 2024-2032, driven by increasing advances in immunotherapy and offering targeted therapies to patients to minimise cancer recurrence.

Nasopharyngeal Cancer Market Overview

Nasopharyngeal cancer is characterized by the presence of cancerous cells in the nasopharynx, which is present behind the nose and above the back of the throat. It is a rare cancer and accounts for less than one case in every 100,000 people per year in the United States. However, the prevalence is higher in South Asia, North Africa, the Middle East, and the Arctic region. In parts of China, there are about 25-30 cases per 100,000 males  and 15-20 per 100,000 females, indicating that men are more likely to develop NPC than women.

A lump in the neck, blood in the saliva, bloody discharge from the nose, nasal congestion or hearing loss are some of the common symptoms of the disease. The risk gradually progresses as a person ages; however, it may affect children as well. In high-risk areas, such as China, the peak age of getting affected by the condition is typically between 45-59. While in the United States (low risk areas), cases are observed in young adulthood (15-24 years of age), followed by a decline until another peak at an older age (65-79).

Growth in FDA Approvals to Meet the Nasopharyngeal Cancer Market Demand

In October 2023, the FDA approved Loqtorzi , the combination of toripalimab, gemcitabine, and cisplatin as a first-tier treatment for adult patients with recurrent or locally advanced nasopharyngeal cancer. The approval was based on the results of phase 3 JUPITER-02 trials, wherein Loqtorzi combined with chemotherapy lowered the risk of disease progression or death by 48%, when compared to therapy alone. In May 2023, the FDA approved the pre-licensing inspection of Shanghai Junshi Biosciences’s manufacturing site in China. This shows that the global nasopharyngeal market share is expected to witness a dynamic shift, with increased production in the Asia Pacific region.

Technical Advancements in Cell Therapies

With a better understanding of biotechnology and gene therapy, researchers are also focused on developing effective therapeutic strategies for treatment. In July 2023, Biosyngen's  cell therapy BRG01 received the fast-track designation by the FDA. BRG01 is an engineered T cell therapy that attacks the human herpesvirus EBBV, which has infected around 95% of the population and has been listed as a Group 1 carcinogen for nasopharyngeal cancer. The nasopharyngeal cancer market growth is fueled by the rising development in new treatment modalities and technologies, aimed at offering personalized treatment approaches to patients.

Application of Dual Immunotherapies to Treat Metastatic Nasopharyngeal Cancer

Conventionally NPC has been targeted with radiotherapy. While it cures around 90% of the patients with the early-stage disease, radiochemotherapy is used in those with advanced NPC. Over the years, immunotherapy has emerged as an active tool for clinical cancer management. Dual immunotherapies such as a combination of PD-1 and CTLA-4 are being investigated in treating NPC, along with other carcinomas. A combination of nivolumab and ipilimumab is currently under phase-2 trials. Therapeutic vaccinations that target EBNA1, LMP1 or LMP2 genes are also under consideration for treating NPC. With the help of such novel therapeutic approaches, scientists and healthcare companies aim to cater to the rising nasopharyngeal cancer market demand and offer effective patient outcomes.

Nasopharyngeal Cancer Market Segmentation

Market Breakup by Therapy

• Chemotherapy

• Immunotherapy

• Radiation therapy

• Others

Market Breakup by Diagnosis

• Biopsy

• MRI

• Others

Market Breakup by Stages

• Stage 1

• Stage 2

• Stage 3

• Stage 4

Market Breakup by End User

• Hospitals

• Clinics

• Others

Market Breakup by Region

• United States

• EU-4 and the United Kingdom
  • Germany
  • France
  • Italy
  • Spain
  • United Kingdom

• Japan

Nasopharyngeal Cancer Market Regional Analysis

Nasopharyngeal cancer is more prevalent in South Asia, therefore, the Asia Pacific region is projected to lead the nasopharyngeal cancer market share in the forecast period. While Japan is the leading market, other countries such India, South Korea and China are also rising as potential markets with increasing investments to build the healthcare infrastructure and upskill the medical staff efficiently.

The United States with a robust medical ecosystem along with research and development infrastructure holds significant portion of the nasopharyngeal cancer market value. The rising number of drug approvals and drug development is driving the market growth in the region. In addition, the presence of vital healthcare companies and stringent regulatory bodies such as FDA ensure the efficacy of therapeutic solutions being offered to patients. There is rising importance on building better diagnostic services that provide precise and prompt results of disease progression in patients.

Europe with countries like United Kingdom, France, Spain, and Italy is another leading market. With multiple academic as well as research institutions, the region leads in devising innovative solutions for the patients. Moreover, there is heavy emphasis on educating the population by reading early signs of nasopharyngeal cancer to facilitate prompt treatment and minimize the risk of mortality.

Nasopharyngeal Cancer Market: Competitor Landscape

In September 2023, Coherus BioSciences, Inc. acquired Surface Oncology, Inc., a clinical-stage immuno-oncology (I-O) company that develops immunotherapies targeting tumour microenvironment. With the acquisition, Coherus aims to expand the application of their recently approved late-stage, anti-PD-1 monoclonal antibody candidate for the potential treatment of advanced recurrent or metastatic nasopharyngeal carcinoma (NPC) – Toripalimab. The agreement also brings three other differentiated clinical assets into the market landscape. Such mergers and partnerships are anticipated to address the unmet needs of people suffering from fatal illnesses.

The key features of the nasopharyngeal cancer market report include patent analysis, grants analysis, clinical trials analysis, funding and investment analysis, partnerships, and collaborations analysis by the leading key players. The major companies in the market are as follows:

• Biocon Limited

• Bristol Myers Squibb

• Cyclacel Pharmaceuticals

• F. Hoffman-La Roche Ltd.

• Merck & Co.

• Novartis AG

• Pfizer

• Sanofi

• Theravectys SA

• Eli Lilly and Company

• GlaxoSmithKline (GSK) PLC

• Celgene Corporation

• BioDiem Ltd

• Fresenius SE & Co. KGaA

Kindly note that this only represents a partial list of companies, and the complete list has been provided in the report.

Key Highlights of the Report